← Leaderboards
Mitesh Borad
Mayo Clinic Arizona
$4,321,070
Attributed
$4,904,441
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,505,282 · 5
FDA$399,159 · 1
By mechanism
DP2$2,709,502 · 1
R01$1,565,901 · 2
UH3$325,709 · 1
P30$303,329 · 2
Top collaborators
- Martin Ernesto Fernandez-Zapico2 shared
Most similar at Mayo Clinic Arizona
Same institution · by research overlap
- Giorgio Inghirami$3,200,984
- Michael T Barrett$3,436,322
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorPre-ClinicalMalignant NeoplasmsVirusViralChemotherapyGenesCellsVesicular Stomatitis Indiana VirusMeasles VirusTransgenesMediatingOncolytic VirusesResearch Clinical TestingResponseGenomeGenomicsPrimary Carcinoma Of The Liver CellsCancer PatientPropertyClinicInterferon-BetaProteinsTissues
Grant awards (11)
New Therapuetics for Pancreatic Cancer$598,329
R01 · FY2025 · CA
New Therapuetics for Pancreatic Cancer$568,413
R01 · FY2024 · CA
HRD-IA signatures in pancreatic ductal adenocarcinoma$325,709
UH3 · FY2024 · CA · contact PI
Gene and Virus Therapy Shared Resource$173,455
P30 · FY2023 · CA · contact PI
Gene and Virus Therapy Program$43,250
P30 · FY2023 · CA · contact PI
Gene and Virus Therapy Program$43,374
P30 · FY2022 · CA · contact PI
Gene and Virus Therapy Program$43,250
P30 · FY2021 · CA · contact PI
Oncolytic Virotherapy in Hepatocellular Cancer$219,502
DP2 · FY2016 · CA · contact PI
Phase 1 Study of VSV-hIFN-B for the Treatment of Hepatocellular Carcinoma$199,637
R01 · FY2016 · FD · contact PI
Oncolytic Virotherapy in Hepatocellular Cancer$2,490,000
DP2 · FY2014 · CA · contact PI
Phase 1 Study of VSV-hIFN-B for the Treatment of Hepatocellular Carcinoma$199,522
R01 · FY2014 · FD · contact PI